Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • OtherEnrolling Location: NSW - Australia

    The use of exenatide, a GLP-1 agonist, in young people with cystic fibrosis related diabetes and impaired glucose tolerance in the management of post prandial glycaemia, gastric emptying and incretins. , protocol number ACTRN12615001029583

    Aim to evaluate the effect of exenatide on postprandial glycaemia in patients with cystic fibrosis related diabetes (CFRD) and impaired glucose tolerance (IGT). CFRD has a detrimental impact on pulmonary function, mortality and prognosis after lung transplant, that is currently treated by intensive insulin regimen, GLP-1 is released in response to food ingestion and is known to stimulate insulin secretion, suppress glucagon secretion and slow gastric emptying. Exenatide is a GLP-1 (glucagon-like peptide1) agonist that can be administered daily without significant risk of hypoglycaemia. It is anticipated that exenatide will normalise postprandial glycaemia. This is a double blinded crossover trail where participants will have 2 study days. On the first day they will receive the intervention or placebo, receiving the opposite on the second day. Once the intervention or placebo has been given, the participant will consume a pancake followed by assessment of glycaemia, incretin response and gastric emptying.

    • Age:

      10 to 25 Years old

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    Excercise alone versus exercise and positive expiratory pressure as a form of airway secretion clearance in adults with mild cystic fibrosis-related respiratory disease - a feasibility study. , protocol number ACTRN12615001361594

    Participants will do four weeks of 'usual' care involving daily breathing exercises (PEP) and walking, running or step ups. After 4 weeks, those who have adhered to these requirements will be randomly allocated to either continue this routine or to stop the PEP and to just continue with the walking, running or step ups for 3 months. Participants will be assessed before and after the four weeks of usual care and at the end of the three month intervention phase.

    • Age:

      18 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceNot yet recruiting Location: NSW, QLD, SA & WA - Australia

    A Phase 3, Randomised, Double-Blind Trial of Inhaled Hypertonic Saline v Isotonic Saline on Lung Structure in CF in children 3-6 Years measured by CT. , protocol number SHIP01 ACTRN12615001067561p

    A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline vs 0.9% isotonic saline for 48 weeks on lung structure in patients with cystic fibrosis in parallel with the North American SHIP trial as measured by CT.

    • Age:

      36 months to 72 months

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      48 weeks

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    The effect of low glucose load diet on glycaemic control in patients with cystic fibrosis , protocol number ACTRN12616001159448p

    Concentrated carbonohydrate loads are often used in CF to help meet increased energy requirements and could have a role in the poor glycaemic control observed in CF. The aim of this project is therefore to establish the feasibility of implementing a low glycaemic load, high calorie dietary management plan for patients with CF and impaired glycaemic status (IGT). A secondary aim is to assess the effect of a low GL diet on clinical outcomes of glycaemic control, lung function and weight. Patients with IGT at the RPA CF clinic will be eligible to participate in this study. Weight glycaemic control, Lung function, diet history and quality of life will be measured at baseline and also at 3 months, following dietary intervention of a low GL diet.

    • Age:

      18 to 45 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Australia, Melbourne

    Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease , protocol number NCT00163696

    Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique

    • Age:

      18-65 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: USA

    Viral pathogenisis of early cystic fibrosis lung disease , protocol number 1R01HL116211-01 NCT01973192

    Study will test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.

    • Age:

      2-4 months

    • Mutation(s):

      Hetrozygous

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-1P-15

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectivness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      3

    • Length of Participation:

      35 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells. , protocol number NCT02564354 PQ-010-002

    This study is taking place at multiple care centers across the U.S. It will explore whether the drug QR-010 administered through nasal spray can increase the movement of salt in and out of the nasal cells.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor. , protocol number Nivalis N91115-2CF1-05

    This study is taking place at multiple care centers across the U.S. It will test the safety and effectiveness of a new type of CFTR modulator drug called N91115 in adults with cystic fibrosis who are currently taking lumacaftor/ivacaftor. It will also look at how the body processes the drug.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 85%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Displaying results 71-80 (of 142)
     |<  <  4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13  >  >|